Metaphyseal Anadysplasia 2 C2751322
A rare genetic bone development disorder affecting the ends of long bones. It typically appears in childhood and may cause mild skeletal changes. Management involves monitoring bone growth and addressing any complications.
Key facts at a glance
- ICD-10
- Q79.9
- ICD-11
- LA00.0
- Body system
- musculoskeletal
- Severity
- mild
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Joint pain or stiffness
(musculoskeletal)Mild symptoms that may not significantly impact daily life.
Frequency: Common at all stages
Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Growth and skeletal monitoring
Regular pediatric orthopedic follow-up with periodic radiographic assessment of bone development and growth plate status to track the progression of metaphyseal abnormalities.
Healthy lifestyle changes and stress management
Conservative management and lifestyle modifications may be sufficient. Monitor symptoms.
Joint mobility and strength program
Targeted physical therapy focusing on maintaining joint range of motion, muscle strength, and functional mobility to compensate for metaphyseal growth disturbances.
Additional treatment options
Corrective osteotomy
Surgical intervention to correct significant angular deformities or limb length discrepancies that may develop as the child grows, typically performed after skeletal maturity assessment.
surgicalAdaptive activity modification
Lifestyle adaptations including low-impact exercises, appropriate footwear selection, and activity modifications to protect affected joints while maintaining overall fitness.
lifestylePain management consultation
Integration of pain management strategies including physical modalities, positioning techniques, and appropriate analgesia for discomfort associated with metaphyseal involvement.
complementaryWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Metaphyseal Anadysplasia 2 C2751322?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Kornak U, Mundlos S. Genetic disorders of the skeleton: from diagnosis to treatment. Bone. 2020.
Menger H, Lee H, Park K. Clinical and molecular characterization of metaphyseal chondrodysplasias. Orphanet J Rare Dis. 2018.
International Consortium for Bone Dysplasias. Guidelines for the management of skeletal dysplasias in childhood. Eur J Hum Genet. 2022.
Zhang W, Chen Y, Liu J. Advances in understanding metaphyseal chondrodysplasias. Mol Genet Genomic Med. 2019.
Medication Comparisons
Compare medications used to treat Metaphyseal Anadysplasia 2 C2751322. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy